Efgartigimod treatment for generalized myasthenia gravis: a single-center case series of 16 patients

BackgroundEfgartigimod was approved in Japan in January 2022 for the treatment of generalized myasthenia gravis (gMG), regardless of antibody status. This case series describes a real-world experience in Japan of efgartigimod treatment for gMG patients with diverse backgrounds.MethodsWe retrospectiv...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Toshiya Nomura, Michie Imamura, Masao Imura, Hironori Mizutani, Mitsuharu Ueda
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2024-10-01
Edice:	Frontiers in Neurology
Témata:	myasthenia gravis autoimmune diseases efgartigimod alfa neonatal Fc receptor case series
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fneur.2024.1472845/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!